(Print or Type Responses)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL						
OMB Number:	3235-0287					
Estimated average burden						
hours per response	0.5					

longer subject to Section 16. Form 4 or Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Form 5 obligations may Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person *- PAYAN DONALD G					2. Issuer Name and Ticker or Trading Symbol RIGEL PHARMACEUTICALS INC [RIGL]							5. Relationship of Reporting Person(s) to Issuer (Check all applicable)X Director 10% Owner					
					3. Date of Earliest Transaction (Month/Day/Year) 03/30/2009						X	X Officer (give title below) Other (specify below) EVP, Pres. Discovery&Research					
(Street)				4. If A	4. If Amendment, Date Original Filed(Month/Day/Year)							6. Individual or Joint/Group FilingCheck Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting Person					
		NCISCO, CA 94											re man one req	Jording Terson			
(Cit	ty)	(State)	(Zip)				Tal	ole I - Non-D	eriva	tive Securities	Acquired,	Disposed of	, or Benefic	ially Owned			
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Yea		ear) Ex			Coc (Ins	Transaction de str. 8)	4. Securities Acqui (A) or Disposed of (Instr. 3, 4 and 5)		(D) Owned Following Transaction(s)		eurities Beneficially g Reported		Ownership Form:	Beneficial			
			(M	onth	/Day/Year)		Code V	Am	ount (A) or (D)	(Instr	(Instr. 3 and 4)		or (I	Indirect (1	Ownership Instr. 4)		
			Table					this fo	orm a	who respond to are not required valid OMB co of of, or Benefic ertible securities	red to resp introl num cially Owne	ond unles ber.				174 (9-02)	
Derivative Conversion Date			Date Execution Date, if	4. Transac Code	5. Number of Derivative Securities			6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Underlying Securities (Instr. 3 and 4)			9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s)	Form of Derivative Security: Direct (D) or Indirect (I)	(Instr. 4)	
				Code	v	(A)	(D)	Date Exercisable		Expiration Date	Title	Amount or Number of Shares		(Instr. 4)	(Instr. 4)		
Stock Option (Right to Buy)	\$ 6.49	03/30/2009		A		145,000		04/30/200)9 <mark>(1)</mark>	03/30/2019	Common Stock	145,000	\$ 0	145,000	D		

Reporting Owners

	Relationships						
Reporting Owner Name / Address	Director	10% Owner	Officer	Other			
PAYAN DONALD G RIGEL PHARMACEUTICALS, INC, , 1180 VETERANS BLVD. SOUTH SAN FRANCISCO, CA 94080	X		EVP, Pres. Discovery&Research				

Signatures

/s/Dolly Vance (Attorney-in-Fact)	03/31/2009
**Signature of Reporting Person	Date

Explanation of Responses:

- If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C.
- (1) The shares vest monthly over one (1) year from the date of grant.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.